Widow
wins top honour for vaccine research
by Thu Van
HA NOI -
When Le Thi Luan, deputy director of the Ministry of Health's Centre for
Research and Production of Vaccines and Biologicals, returned to work after
taking two weeks off, her colleagues were silent. They did not know what to
say.
Luan quickly changed her clothes and went directly into the
laboratory. Her calm voice and demeanour told her colleagues that it was
business as usual, and they got to work. They gave her an update on what had
happened during her absence and she chaired a discussion on what they would
do next.
It was a Monday morning in September 2003. Luan had taken two
weeks off because her husband had died of a disease about which little is
known to the world to date. (She did not want to dwell on the topic.)
At the end of that day, she returned home and had dinner with
her 15-year-old daughter and 11-year-old son, who were still in shock after
their father's death. He used to take care of every little and big thing for
them so that their mother could devote all the time she wanted for her
research.
Luan is the head of a research project for domestic production
of a rotavirus vaccine, which began in 1998. At that time, there were only
two kinds of
Five years after starting the research project, success was
nowhere near for Luan, but now she was saddled with all the tasks that her
husband used to do for their family.
She would also have to carry on with the project. That night,
Luan cried before going to bed, and thought of her husband.
This routine did not vary for the next 11 years.
A long
journey
On March 8, 2014, Luan stepped on the stage to receive the Kovalevskaia
Prize, named after the Russian mathematician and advocate of women's rights,
Sofia Kovalevskaya.
She had been chosen for an award that aims to encourage
Vietnamese women to advance themselves and contribute to the nation's
progress.
Fifteen years after she began working on producing Rotavin-M1,
an anti-diarrhoea vaccine for children, the "made-in-Vietnam"
rotavirus vaccine was introduced to domestic market in 2012.
As she walked to the stage, Luan's thoughts went to the old,
small almost deserted health clinic in her village in
It was located at the end of the village, near a big tree,
which made it look very lonely. Luan, the second eldest child in the family,
had taken her mother there four times when she was in labour, and countless
other times when her younger sisters fell sick.
There was nothing but an old bed inside the clinic and one or
two nurses who would give patients pills for normal pains and illnesses. If
someone had a serious health problem, there was no point in going to the
clinic. They would have to walk several miles to get to the district
hospital, and if they couldn't walk, they would have to be carried on an
old-style hammock. There were people who died on the way.
These memories motivated her to become a doctor.
When she graduated after nine years of study from the Ha Noi
Medical University, Professor Hoang Thuy Nguyen, a leading virus expert and
vaccine researcher in
No
short-cuts
The initiative to produce the rotavirus vaccine was taken in
1998 when Luan took part in a World Health Organisation programme to prevent
diarrhoea among Vietnamese children. Rotavirus was then the leading cause of
severe diarrhoea afflicting children worldwide. According to the most recent
World Health Organisation (WHO) estimates, rotavirus is responsible for more
than 500,000 child deaths every year. Most deaths occur in developing
countries.
Reflecting on the 15 long years it had taken for the research
and production to succeed, Luan said it was well worth every effort and well
worth the patience it had demanded and taken.
"There were times when we failed and failed again. What I
learned from this is that you have to be calm in every situation, and figure
out the next steps." Although she was speaking of calmness, there was
some excitement in her voice as she recalled the progress made in making the
vaccine.
It took three years to carry out surveys on children with
diarrhea in the country so as to identify peculiarities and important
features in the local epidemiology of the disease.
Then it took another five years to isolate and characterize
three human rotavirus strains being considered for further vaccine
development.
There were factors that made this work even more difficult,
Luan recalled.
"Doing scientific research in
Luan has a PhD in Virology.
The rotavirus candidate was then evaluated for two years on
African blue monkeys which were being bred on
"It was a tough time. When we tried the vaccine on 200
children, my colleagues and I couldn't sleep well for a whole month and
always had to keep our phone on," Luan recalled.
But the tension and the hard work produced results.
Rotavin was evaluated by the US Centre for Disease Control and
Prevention, and approved for use by the National Institute for Control of
Vaccines and Biologicals in July, 2011.
Since then, nearly 100,000 children in 60 cities and provinces
have received the vaccine, which costs one-third the price of imported
products. In
"From a country that was totally dependent on imported
vaccine,
Luan took the award she'd just won in her stride with the same
calmness she had faced adverse circumstances, staying focused on the bigger
prize.
"The Kovalevskaia Prize, or any other prize, is not my
final destination. When you're working on the production of something, what
you want most is the successful product." - VNS
|
Thứ Ba, 18 tháng 3, 2014
Đăng ký:
Đăng Nhận xét (Atom)
Không có nhận xét nào:
Đăng nhận xét